Comparative assessment of the toxicity of different induction chemotherapy regimens for oropharyngeal squamous cell carcinoma

Golubev P.V.; Bolotina L.V.; Gevorkov A.R.; Deshkina T.I.

doi:https://doi.org/10.17116/onkolog20221105131

Golubev P.V.

Herzen Moscow Research Cancer Institute

Bolotina L.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia

SPIN RSCI: 2787-5414
Scopus AuthorID: 6603382243
ResearcherID: U-5441-2019
ORCID: 0000-0003-4879-2687

Gevorkov A.R.

P.A. Herzen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Center of the Ministry of Health of the Russia

Deshkina T.I.

P.A. Herzen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Center of the Ministry of Health of the Russia

Comparative assessment of the toxicity of different induction chemotherapy regimens for oropharyngeal squamous cell carcinoma

Authors:

Golubev P.V., Bolotina L.V., Gevorkov A.R., Deshkina T.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(5): 31‑37

DOI: 10.17116/onkolog20221105131

Read: 1929 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Golubev PV, Bolotina LV, Gevorkov AR, Deshkina TI. Comparative assessment of the toxicity of different induction chemotherapy regimens for oropharyngeal squamous cell carcinoma. P.A. Herzen Journal of Oncology. 2022;11(5):31‑37. (In Russ.)
https://doi.org/10.17116/onkolog20221105131

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To improve the results of treatment in patients with locally advanced human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma, by optimizing the induction chemotherapy (ICT) regimen, using a two-component combination in particular.

SUBJECTS AND METHODS

Since 2021, the investigation has enrolled 13 patients with locally advanced HPV-positive oropharyngeal squamous cell carcinoma. At the first stage of combination treatment, all the patients received 3 cycles of ICT according to the DC (docetaxel 75 mg/m2 + cisplatin 75 mg/m2) regimen for 21 days. Further, all the patients were scheduled to use chemoradiotherapy (CRT) of SOD 70 Gy during radio modification with carboplatin AUC 2.0. The primary endpoints following ICT were the assessment of an objective response and toxicity. The secondary endpoints were the estimation of an objective response rate after the second stage of combination treatment, 1-year overall survival, and progression-free one.

RESULTS

The objective response rate and toxicity were assessed for all the patients. There was a complete response in 2 (15%) patients, a partial response in 5 (38%), and disease stabilization in 5 (38%). Toxicity was assessed using the scales CTC — NCIC V5.0. No cases of grade 3—4 leukopenia were noted. There was grade 1—2 anemia in 4 (31%) patients and grade 1—2 thrombocytopenia in 2 (15%).

CONCLUSION

The proposed two-component ICT regimen has demonstrated an acceptable toxicity profile. If comparable survival rates are achieved with the existing standard, this ICT regimen can be considered as a new standard for real clinical practice in the treatment of patients with locally advanced HPV-positive oropharyngeal squamous cell carcinoma.

Keywords:

squamous cell carcinoma

oropharyngeal cancer

human papillomavirus

induction chemotherapy

toxicity

Authors:

Golubev P.V.

Herzen Moscow Research Cancer Institute

Bolotina L.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia

SPIN RSCI: 2787-5414
Scopus AuthorID: 6603382243
ResearcherID: U-5441-2019
ORCID: 0000-0003-4879-2687

Gevorkov A.R.

P.A. Herzen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Center of the Ministry of Health of the Russia

Deshkina T.I.

P.A. Herzen Moscow Oncology Research Institute - Branch of the National Medical Radiology Research Center of the Ministry of Health of the Russia

Received:

08.04.2022

Accepted:

31.05.2022

Close metadata

References:

Kaprin AD, Starinskii VV, Petrova GV. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2018. M.: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2019. (In Russ.).
Sedakov IE, Semikoz NG, Komendant VV, Gonchar AG, Chistyakov AA, Polzikov GN. Sovremennye aspekty lecheniya ploskokletochnogo raka golovy i shei. Novoobrazovanie. 2018;10(2):44-50. (In Russ.). https://doi.org/10.26435/neoplasm.v10i2.250
Nakano K, Seto A, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H, Mitani H, Takahashi S. Predictive factors for completion of TPF induction chemotherapy in patients with locally advanced head and neck cancer. Anticancer Res. 2019;39(8):4337-4342. https://doi.org/10.21873/anticanres.13601
Gau M, Karabajakian A, Reverdy T, Neidhardt EM, Fayette J. Induction chemotherapy in head and neck cancers: results and controversies. Oral Oncol. 2019;95:164-169. https://doi.org/10.1016/j.oraloncology.2019.06.015
Saito Y, Ando M, Omura G, Yasuhara K, Yoshida M, Takahashi W, Yamasoba T. Induction chemotherapy for p16 positive oropharyngeal squamous cell carcinoma. Laryngoscope Investig Otolaryngol. 2016;1(2):28-32. https://doi.org/10.1002/lio2.18
Bhattasali O, Han J, Thompson LDR, Buchschacher GI Jr, Abdalla IA, Iganej S. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease. Oral Oncol. 2018;78:151-155. https://doi.org/10.1016/j.oraloncology.2018.01.031
Tam M, Hu K. Regional radiation therapy for oropharyngeal cancer in the HPV era. Semin Radiat Oncol. 2019;29(2):126-136. https://doi.org/10.1016/j.semradonc.2018.11.011
Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP; Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013;31(23):2854-2860. https://doi.org/10.1200/JCO.2012.47.7802
Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, ± docetaxel for larynx preservation. J Natl Cancer Inst. 2016;108(4):djv368. https://doi.org/10.1093/jnci/djv368
Patel RR, Ludmirb EB, Augustyn A, Zaorsky NG, Lehrer EJ, Ryali R, Trifiletti DM, Adeberg S, Amini A, Verma V. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: a systematic review of prospective trials. Oral Oncol. 2020;103:104608. https://doi.org/10.1016/j.oraloncology.2020.104608
Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, Beitler JJ, Gross N, Jones CU, Kaufman M, et al. Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37(18):1578-1589. https://doi.org/10.1200/JCO.19.00441
Radzhapova MU, Mardynskii YuS, Gulidov IA, Medvedev VS, Semin DYu, Ivanova IN. Khimioluchevaya terapiya bol’nykh rakom slizistoi obolochki polosti rta i rotoglotki s ispol’zovaniem neravnomernogo drobleniya dnevnoi dozy. Sibirskii onkologicheskii zhurnal. 2011;3:35-39. (In Russ.).
Gevorkov AR, Boiko AV, Polyakov AP, Bolotina LV, Volchenko NN, Rebrikova IV, Lemeshko AM, Shashkov SV. VPCH-otritsatel’nyi rak rotoglotki kak otdel’naya prognosticheski neblagopriyatnaya nozologicheskaya forma, trebuyushchaya novykh podkhodov k lecheniyu (klinicheskoe nablyudenie). Opukholi golovy i shei. 2019;9(2):71-80. (In Russ.). https://doi.org/10.17650/2222-1468-2019-9-2-71-80
Bolotina LV, Deshkina TI, Kornietskaya AL, Kravtsov SA, Ustinova TV, Paichadze AA, Kaprin AD, Fedenko AA. Vliyanie rezul’tatov mezhdunarodnykh issledovanii na vybor lechebnoi taktiki pri nerezektabel’nykh formakh ploskokletochnogo raka golovy i shei. Opukholi golovy i shei. 2020;10(2):10-21. (In Russ.). https://doi.org/10.17650/2222-1468-2020-10-2-10-21
Golubev PV, Bolotina LV, Gevorkov AR, Deshkina TI. A current view on the possibility of treatment volume de-escalation in HPV-associated oropharyngeal squamous cell carcinoma. P.A. Herzen Journal of Oncology = Onkologiya. Zhurnal im. P.A. Gertsena. 2021;10(3):47-53. (In Russ.). https://doi.org/10.17116/onkolog20211003147
Thompson LDR, Burchette R, Iganej S, Bhattasali O. Oropharyngeal squamous cell carcinoma in 390 patients: analysis of clinical and histological criteria which significantly impact outcome. Head Neck Pathol. 2020;14(3):666-688. https://doi.org/10.1007/s12105-019-01096-0
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35. https://doi.org/10.1056/NEJMoa0912217
Misiukiewicz K, Gupta V, Miles BA, Bakst R, Genden E, Selkridge I, Surgeon JT, Rainey H, Camille N, Roy E, et al. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: the Quarterback trial. Oral Oncol. 2019;95:170-177. https://doi.org/10.1016/j.oraloncology.2019.06.021
Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, et al. Evaluation of substantial reduction in elective radiotherapy dose and field in patients with human papillomavirus—associated oropharyngeal carcinoma treated with definitive chemoradiotherapy. JAMA Oncol. 2022;8(3):364-372. https://doi.org/10.1001/jamaoncol.2021.6416
Schaner PE, Chandra RA. Decreasing the dose and volume of elective nodal radiotherapy in HPV-associated oropharyngeal cancer: how low can we go? JAMA Oncol. 2022;8(3):372-373. https://doi.org/10.1001/jamaoncol.2021.6411
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RL, Dekker A, Kochanny S, et al. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019;30(2):297-302. https://doi.org/10.1093/annonc/mdy522
Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, Nolè F, Verri E, Orecchia R, Morelli F, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017;28(9):2206-2212. https://doi.org/10.1093/annonc/mdx299
Okano S, Enokida T, Onoe T, Ota Y, Motegi A, Zenda S, Akimoto T, Tahara M. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer. Int J Clin Oncol. 2019;24(7):789-797. https://doi.org/10.1007/s10147-019-01418-w